A First-in-Class, Non-Surgical Solution for Obesity Approved for One-Year of Device Treatment, Offering Patients Potentially More Durable Weight Loss and Health Benefits SAN CARLOS, Calif., April 23, 2019 /PRNewswire/ — BAROnova, Inc., a medical device company focused on the development of first-in-class …
Trending at Lumira Ventures
BAROnova’s TransPyloric Shuttle® (TPS®) Positive Pivotal Trial Data Presented at the 2018 Obesity Week Conference
Individuals Treated with TPS lost 3-fold More Weight Than Those in Sham-Controlled Placebo Arm SAN CARLOS, Calif., Nov. 15, 2018 /PRNewswire/ — BAROnova, Inc., a clinical stage medical device company focused on the development of non-surgical solutions for the treatment of …
BAROnova Announces Submission of Premarket Approval (PMA) Application to the U.S. FDA for the TransPyloric Shuttle® (TPS®) Device Intended for the Treatment of Obesity
SAN CARLOS, Calif., /PRNewswire/ — BAROnova, Inc., announced today that it has submitted a Pre-Market Approval (PMA) application for the TransPyloric Shuttle device intended for the treatment of obesity to the Food and Drug Administration (FDA). Obesity is a worldwide epidemic with …
BAROnova Announces Completion of ENDObesity® II Pivotal Clinical Trial Enrollment
SAN CARLOS, Calif., Jan. 25, 2017 /PRNewswire/ — BAROnova, Inc., announced completion of its randomized cohort enrollment in the ENDObesity II Study, a multicenter randomized pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle® (TPS®), …
BAROnova Announces Appointment of David S. Thrower as President and Chief Executive Officer
GOLETA, Calif., May 4, 2016 /PRNewswire/ — BAROnova, Inc., a medical technology company developing devices for the treatment for obesity, today announced the appointment of David S. Thrower as President and Chief Executive Officer. Mr. Thrower will also become a member …
The steady and successful climb of BaroNova
Welcome to the Medsider interview, a special new feature at MassDevice, which will appear regularly. All interviews are conducted by Scott Nelson, Founder, Medsider. We hope you enjoy them. Henry Ford is famous for stating, “If I had asked …
BAROnova Announces Enrollment of First Patients in the ENDObesity II Pivotal Clinical Trial
GOLETA, Calif., Dec. 11, 2015 /PRNewswire/ — BAROnova, Inc., announced today the enrollment of the first four patients in its ENDObesity® II Study, a twelve-month multicenter pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle® …
BAROnova Closes $36.5 Million Series D Financing
GOLETA, Calif., Nov. 23, 2015 /PRNewswire/ — BAROnova, Inc., today announced it has closed a Series D financing of $36.5 million. Delos Capital led the round and Longitude Capital co-led the round, with participation from existing investors Lumira Capital Partners, …
BAROnova – Makes the 2013 Fierce 15 for Medical Devices
Learn More-External Link
BAROnova® Announces the Results of ENDObesity® I Clinical Trial
New Non-Surgical Medical Device Achieves Surgical-Level Weight-Loss Results and Has the Potential to be Safer and More Cost-Effective than Bariatric Surgery Goleta, Calif., April 22, 2013 /PRNewswire/ — BAROnova, Inc., recently presented data from their ENDObesity I clinical …
BAROnova Secures $27.3M Investment To Fund Clinical Trial For Weight-loss Device
GOLETA, Calif., Feb. 15, 2013 — /PRNewswire/ — BAROnova, Inc., announced today the closing of its Series C financing of $27.3 million, led by investments from Sante Ventures and Boston Scientific Corporation (NYSE:BSX), a leading innovator of medical devices and …